SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

BACKGROUND AND OBJECTIVES: The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in genotype 3 (GT3) with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangia, Alessandra, Piazzolla, Valeria, Giannelli, Anna, Visaggi, Egidio, Minerva, Nicola, Palmieri, Vincenzo, Carraturo, Immacolata, Potenza, Domenico, Napoli, Nicola, Lauletta, Gianfranco, Tagarielli, Vincenzo, Santoro, Rosanna, Piccigallo, Ernesto, De Gioia, Sergio, Chimenti, Angelo, Cuccorese, Giuseppe, Metrangolo, Antonio, Mazzola, Michele, Agostinacchio, Ernesto, Mennea, Giuseppe, Sabbà, Carlo, Cela, Marina, Copetti, Massimiliano, Losappio, Ruggiero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519817/
https://www.ncbi.nlm.nih.gov/pubmed/31091254
http://dx.doi.org/10.1371/journal.pone.0215783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519817/
https://www.ncbi.nlm.nih.gov/pubmed/31091254
http://dx.doi.org/10.1371/journal.pone.0215783

Ejemplares similares